Pharmacology Flashcards

(298 cards)

1
Q

What are the types and effects of adrenergic receptors?

A

Stimulate alpha-1 and beta-1 receptors.
Inhibit alpha-2 and beta-2 receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What do alpha-1 receptors work on?

A

Alpha 1 receptors are adrenergic receptors.
GQ protein coupled to produce stimulatory effect
Found in:
- blood vessels –> Vasoconstriction
Certain smooth muscles of urogenital tract –> contraction e.g. oppose voiding bladder and ejactulation.
- glands –> secretion
- GI tract –> relaxation

Agonist: phenylephrine
Antagonist: prazosin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What do beta-1 receptors work on?

A

Found in:
- Heart
SA note –> increase rhythmicity increase heart rate
AV node –> increase conduction velocity
ventricular myocytes –> increase contractility
- Juxtaglomerular cells in kidneys –> increase renin release

Selective agonist: Dobutamine
Selective antagonist: metoprolol, atenolol, etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What do Beta 2 receptors act on?

A

Found in:
Bronchi –> Bronchodilation
Blood Vessels –> vasodilation
uterus –> relaxation
GI tract –> relaxation
Pancreas –> glucagon secretion
Eye –> increase aqueous secretion
Detrusor muscle –> relaxation

Selective agonist: Salbutamol, terbutaline
Selective antagonist: alpha-methyl propanolol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What do beta 3 receptors act on?

A

Found in adipose tissue and detrusor muscle to cause relaxation
Selective agonist: mirabegron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the effects of the dopamine and its receptors when stimulated?

A

Dopamine is a catecholamine that has mixed adrenergic effects.
It has little alpha-adrenergic effects

lower doses (0.5-3mcg/kg/min): Dilate renal mesenteric coronary vascular beds. Useful in oliguric renal failure.

higher doses (5-13 mcg/kg/min): has beta-1 adrenergic agonist affects resulting in vasodilation. Can be used to improve cardiac output by decreasing afterload.

Dose range: 1-20mcg/kg/min. Discontinue if tachycardic or arrhythmic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the effects of norepinephrine?

A

Norepinephrine is a mixed adrenergic agonist with a stronger effect on alpha-1 receptors than beta receptors.

It causes increased vasoconstriction.
It will commonly lower heart rate on account of baroreceptor reflex with increased blood pressure
Caution: Large dose of norepinephrine can cause profound bradycardia

Concern: to much vasoconstriction increases afterload causing decreased cardiac output.

Dose: 0.1 - 2mcg/kg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the effects of phenylephrine?

A

Phenylephrine is an alpha-1 agonist.
Indicated for hypotension when beta-adrenergic agonist effects are not desirable.
Can cause increased blood pressure and bradycardia.
too much vasoconstriction can increase afterload and decrease output. (Use with caution in patient with bradycardia or cardiac disease).

Dose: 0.1-2mcg/kg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the effects of vasopressin?

A

Vasopressin is also known as anti-diuretic hormone.

It causes vasoconstriction independent of adrenergic stimulation.
It is commonly used in conjunction with norepinephrine for refractory hypotension.
Vasopressin is not affected by pH making it ideal for use during prolonged CPR.

Dose: 0.01-0.04units/kg/min
Strength: 0.01units/ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the effects of epinephrine?

A

Epinephrine is a mixed adrenergic agonist with both alpha 1 and beta one agonist properties

Low dose: beta-adrenergic effects predominate improving cardiac output and cardiac contractility

higher doses: more of an alpha-1 adrenergic agonist resulting in vasoconstriction.

CRI dose: 0.1-2.0mcg/kg/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What do alpha-2 receptors work on?

A

Gi/Go coupled proteins acting on adenylyl cyclase cAMP pathway to produce inhibitory effects

receptors located prejunctional in nerve endings to inhibit transmitter release
Receptors in the brain decrease sympathetic flow
receptors in the pancreatic beta cells inhibit the release of insulin
Alpha 2 promotes platelet aggregation
receptors in the blood vessels induces vasoconstriction

results in profound sedative and analgesic qualities. Alpha-2 are effective emetics in cats

Agonist: Clonidine, dexmeditomidine, xylazine
Antagonist: Yohimbine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cholinergic Muscarinic receptors

A

Involved in peristalsis, micturition, bronchoconstriction and several other parasympathetic reactions.

Muscarinic receptors are type of ligand-gated G-protein coupled receptor and are linked to second messenger systems.

Muscarinic receptor varies with the receptor subtype.

These receptors occur in the CNS and the autonomic parasympathetic division of the PNS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cholinergic receptors

A

Two types of cholinergic receptors: Nicotinic and muscarinic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cholinergic nicotinic receptors

A

Found on skeletal muscles in the autonomic division of the peripheral nervous system and in the central nervous system.

Nicotinic receptors are monovalent cation channels through which both sodium and potassium can pass.

Nicotinic receptors divided into two subtypes:
N1 - peripheral neuromuscular junction - muscle contraction, if on adrenal glands - release adrenaline and norepinephrine
N2 - central nervous systemor neuronal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Adrenergic receptors

A

Are divided into two classes (alpha and beta) with multiple subtypes each.

Adrenergic receptors are linked to G proteins and initiate a second messenger cascade.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Glutaminergic Receptors

A

Metabotropic glutaminergic receptors act through G-protein-coupled receptors. Two types of glutaminergic receptors are receptor channels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Glutamate

A

The main excitatory neurotransmitter in the CNS and also acts as a neuromodulator.

Action of glutamate at a particular synapse depends on which of its receptor types occurs on the target cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

alpha amino-3-hydroxy-5 methylisoxazole-4-proprionic acid)

AMPA receptors

A

Ligand-gated monovalent cation channels are similar to nicotinic acetylcholine channels.

Glutamate binding opens the channel, and the cell depolarizes due to net sodium influx.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

N-methyl-D-aspartate

NMDA receptors

A

cation channels that allow sodium, potassium, and calcium to pass through the channel

Channel opening requires both glutamate binding and a change in membrane potential.

NMDA receptor channel is blocked by magnesium ions at resting membrane potentials.

Glutamate binding opens the ligand-activated gate, but ions cannot flow past the magnesium. If the cell depolarizes, the magnesium blocking the channel is expelled, and ions flow through the pores.

The NMDA receptor is a CNS receptor that ultimately has an excitatory effect CNS effect. Activation of NMDA receptors has been associated with altered modulation pathways and the formation of chronic pain including hyperalgesia, allodynia and reduced functionality of opioid receptors.

Ketamine is believed to be an NMDA antagonist that essentially shus off the NMDA receptor and believed to prevent and treat hyperalgesia and allodynia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Hyperalgesia

A

phenomenon resulting in prolonged exposure of receptors to noxious stimuli, leading to stimulus that should cause mild pain producing an excessive sense of pain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

allodynia

A

a type of nerve pain that causes pain from stimuli that normally wouldn’t cause pain. e.g. a mild stimulus may feel more painful when sunburned or inflammed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Gamma-aminobutyric acid type A (GABA A)

A

Ligand-gated ion channels that allow chloride ions to pass into cells.

one of the body’s main inhibitory transmitters. When stimulated will suppress excitability in the central nervous system.

Drugs that stimulate GABA A receptors: Avermectins, Benzodiazepines, propofol, Etomidate, Alfaxalone

Conditions that increase activity of GABA system: hepatic encephalopathy

Drugs that will decrease GABA: Metaldhyde, Lead interferes with GABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What does ACEi stand for? What does it do?

A

Angiotensin-converting enzyme inhibitors that disrupt the renin-angiotensin-aldosterone system (RAAS).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Which organs does angiotensin II act on and what is the outcome of its mechanism of action?

A

Converted from Angiotensin I by angiotensin-converting enzyme (ACE)
Angiotensin II is a hormone that binds to receptors in various tissues to exert various effects.

Acts on the adrenal cortex, causing it to release aldosterone.

stimulates vasoconstriction in systemic arterioles

Promotes sodium reabsorption in proximal convoluted tubules of the kidneys.

In the CNS:
It acts on the hypothalamus to stimulate thirst and encourage water intake
It induces the posterior pituitary to release antidiuretic hormone
It reduces the sensitivity of the baroreceptors’ response to increase blood pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What is the role of angiotensin-converting enzyme?
It converts Angiotensin I to angiotensin II.
26
What are some effects of angiotensin-converting enzyme inhibition (ACEi)?
decrease proteinuria promote vasodilation and ventilation reduce plasma volume All of the above sums to decrease systolic blood pressure ACEi can also decrease the metabolism of vasodilatory agent bradykinin resulting in decrease in vascular tone.
27
What is first line of treatment for systemic hypertension in dogs?
ACE inhibitors
28
What are two of the most common ACEi?
Enalapril and Benazepril
29
Is ACEi a recommended first line treatment for SHT in cats? Why?
ACEi is not a recommended fist line treatment for cats as it does not sufficiently nor consistently lower blood pressure. Benazepril may be beneficial in conjunction with calcium channel blocker.
30
What is the concern with ACEi in patients who are dehydrated or azotemic?
There is potential to worsen glomerular filtration rate and renal function through preferential dilation of the efferent arteriole that would thereby decrease glomerular filtration pressure. Overall risk is low unless the patient also being treated with diuretic therapy or the patient has severe azotemia.
31
Which electrolyte imbalance might ACEi administration contribute?
hyperkalemia secondary to inhibition of aldosterone. However, this is unlikely to be clinically relevant event when given in conjunction with aldosterone antagonist such as spironolactone.
32
What effects do angiotensin receptor blockers (ARBs) exert?
Blocks the ability of angiotensin II to activate its receptors. It does not affect the metabolism of bradykinin.
33
What is a contraindication for angiotensin receptor blockers (ARBs)?
Do not use in severely dehydrated or azotemic patients
34
What class of drug is Spironolactone?
aldosterone antagonist
35
How do aldosterone antagonist exert their effects?
Block the effects of aldosterone on the distal convoluted tubule and collecting duct.
36
Aldosterone
It is a steroid hormone produced by the adrenal cortex when stimulated by Angiotensin II. It helps control the balance of water and salts in the kidney by keeping sodium and releasing potassium from the body.
37
What are the effects of chronic exposure to aldosterone?
Induces vascular remodeling in the glomerulus to retain sodium and water resulting in systemic hypertension. Aldosterone also exerts proinflammatory effects promoting fibrosis.
38
What is a primary indication for use of spironolactone?
Hyperaldosteronism
39
When is it reasonable to suspect hyperaldosteronism in cats?
hypertension hypernatremia hypokalemia mostly in chronic kidney disease
40
What is a potential adverse effect of spironolactone?
development of hyperkalemia. However, this is unlikely unless used with ACEi, ARBs or Beta blocker
41
Dihydropyridines
Dihydropyridines are a type of calcium channel blocker (CCB) that block calcium channels located in the muscle cells of the heart and arterial blood vessels, thereby reducing the entry of calcium ions into the cells. By blocking these channels, CCBs promote: vasodilation increase strength in contractility minimal effect on cardiac conduction though the decrease in blood pressure may trigger a reflex tachycardia. E.g. Amlodipine and Nicardipine
42
What is first line treatment for antihypertensives in cats?
Amlodipine because it has shown to be more effective than ACEi. If the cat is refractory to amlodipine, then it may require an addition of ACEi or ARB
43
Side effects of CCBs
Reflex tachycardia weakness, lethargy and decrease in appetite intrarenal hemodynamics --> CCB promotes preferential afferent arteriolar dilation over the efferent arteriole, which may result in increased intraglomerular pressure, resulting in damage to the glomerulus and worsening proteinuria.
44
Adrenergic Antagonist
It can help manage SHT, especially if the underlying mechanism is sympathetically driven.
45
Prazosin
Selective alpha 1 antagonist to promote smooth muscle vascular relaxation.
46
Acepromazine
Dopamine antagonist with the potential to cause hypotension and GI upset
47
Atenolol
Beta 1 selective antagonist Decreases heart rate and contractility Reduces renin release and peripheral vascular resistance Used more in cats with SHT and hypethyroidism Used in dogs as adjunct for refractory SHT with reflex tachycardia
48
Propanolol
Non-selective beta antagonist Decreases heart rate and contractility Reduces renin release and peripheral vascular resistance
49
What is an adverse side effect of atenolol
Excessive bradycardia
50
Labetalol
Injectable mix of alpha and beta antagonists. Used to manage severe acute hypertension promotes vasodilation and prevents associated tachycardia The use has been explored in dogs undergoing craniotomy or adrenalectomy
51
Hydralazine
Promotes vasodilation by altering smooth muscle intracellular metabolism. works primarily on arteries Causes vasodilation, afterload reduction and lowering of blood pressure The mechanism is not entirely understood but the end result is smooth muscle relaxation and decrease in peripheral vascular resistance. It is not used as a first-line drug but used as an adjunct in chronic management. Injectable form used in urgent/emergent treatment due to its potent vasodilatory effects, and rapid onset.
52
What are adverse side effects to hydralazine?
Arteriolar vasodilator excessive or irreversible hypotension reflex tachycardia sodium and water retention GI upset
53
Sodium nitroprusside (SNP)
Arteriolar vasodilator promotes potent vasodilation through release of nitric oxide. Nitric oxide diffuses to vascular smooth muscle decrease influx of calcium, activation of actin/myosin chains and overall contractile forces Effects: smooth muscle relaxation and decreased vascular tone and peripheral vascular resistance The injectable form has a short half-life and is easy to titrate, so it is ideally used for hypertensive crises. Administer as CRI. Used to treat acute hypertensive crises or fulminant CHF Contraindicated in hypotensive patients
54
IV nitroglycerine
promotes potent vasodilation through release of nitric oxide. Nitric oxide diffuses to vascular smooth muscle decrease influx of calcium, activation of actin/myosin chains and overall contractile forces Effects: smooth muscle relaxation and decreased vascular tone and peripheral vascular resistance The injectable form has a short half-life and is easy to titrate, so it is ideally used for hypertensive crises. No risk of cyanide poisoning
55
What are the adverse side effects associated with sodium nitroprusside?
generation of cyanide and thiocyanate at high doses and prolonged use. Patients with kidney and liver disease have decreased metabolism, therefore greater risk of cyanide toxicity. Clinical signs of toxicosis: metabolic acidosis, depression, stupor, seizures
56
Fenoldopam
Selective agonist of dopamine 1 receptor. Promotes peripheral and renal vasodilation and natriuresis Increases glomerular filtration rate Injectable has a short half life. Good potential for application in hypertensive crisis, but needs further investigation in vet med.
57
Class 1 Antiarrhythmics
Sodium channel blockers Interferes intracellularly with sodium conduction through sodium channels Subclassification determined by potency of effects on sodium channel, activated/inactivated blockade and effects on other channel receptors.
58
Class 1A antiarrhythmic agents
Quinidine and procainamide Effective against ventricular and supraventricular arrhythmias. fast sodium channel blocking effects and moderate blockade of rapid component of the delayed rectifier potassium current resulting in action potential elongation.
59
Procainamide
Class 1 A antiarrhythmic Sodium channel blocker Depresses conduction velocity and prolongs refractory period in a variety of tissues, including atrial and ventricular myocardium Administer slowly IV over 5-10 minutes to prevent hypotension Adverse effects more commonly associated with cats and humans; include anorexia, nausea, and vomiting
60
Class IB Antiarrhythmic
Inhibits fast sodium channels, primarily in the open and inactivated state, with rapid onset. Sodium current is also inhibited, resulting in the shortening of action potential in normal myocardial tissue Lidocaine and mexiletine
61
Lidocaine
Class IB antiarrhythmic Sodium channel blocker. The ability of lidocaine to block sodium currents is better during acidosis. Benefit: minimal hemodynamic, SA, AVN affect at standard doses Hepatic clearance determines serum concentration Heart failure, hypotension, and severe hepatic disease can decrease lidocaine metabolism and predispose patients to lidocaine toxicity. Adverse effects: higher incidence in cats Nausea, vomiting, lethargy, tremors, seizure activity (usually symptoms stop when lidocaine is discontinued) Dosing: Bolus 2mg/kg over 20-30 seconds; bolus can be repeated up to 8mg/kg within 10 minute period barring adverse effects CRI: 25-75mcg/kg/min
62
Mexiletine
Class 1B antiarrhythmic most common oral class in dogs Highly protein-bound and excreted by the kidneys Use and adverse effects similar to Lidocaine (rarely used in cats because of adverse effects)
63
Tocainide
Class 1B antiarrhythmic Similar to lidocaine, rarely used in small animals because of high incidence of serious adverse effects including renal failure and corneal dystrophy
64
Class 1C Antiarrhythmic
Potent blockade of the open state fast sodium channel with greater effects as the depolarization rate increases These agents prolong the refractory period in atrial and ventricular tissues Propafenone and Flecainide
65
Propafenone
Class 1C antiarrhythmic used to treat narrow complex tachyarrhythmias usually combined with diltiazem also has mild beta blocking properties
66
Flecainide
Class 1C antiarrhythmic potent negative inotropic properties Side effects include GI, but not commonly seen Rarely used in veterinary medicine Monitor heart rate, blood pressure and ECG when administering
67
Class II antiarrhythmic
Beta-adrenergic antagonists or beta-blockers are the most used cardiovascular drugs. Must be cognizant of animals' underlying disease when prescribing. Beta-blockers contraindicated in patients with evidence of sinus nodal dysfunction, AVN conduction disturbances, pulmonary disease or CHF (must be evaluated for fluid retention and condition must be stabilized before implementing beta-blockade). Reduces heart rate and myocardial oxygen demand and increases atrioventricular conduction time. Inhibits pacemaker current I(f) that promotes proarrhythmic depolarization in damaged cardiomyocytes Inhibits calcium current by decreasing tissue cyclic adenosine monophosphate levels ; the magnitude of effects depends on the sympathetic state. Greater effect with higher adrenergic states Beta-adrenergic antagonists slow AVN conduction in SVT by slowing sinus discharge rate in inappropriate sinus tachycardia and suppresses ventricular tachycardia that may be exacerbated by increased sympathetic tone. Used to treat supraventricular and ventricular arrhythmias. Also used in HCM to control heart rate and decrease myocardial oxygen demand Can cause hypotension due to decreased heart output. Extremely low dosages must be used with patients with systolic myocardial dysfunction. Because of that, beta blockers are not generally first choice for acute anti-arrhythmic therapy because the amount required is not well tolerated.
68
Propranolol
Non-selective beta receptor antagonist (targets both beta-1 and 2 receptors). Function: decrease heart rate and contractility. Decrease renin release and peripheral vascular resistance
69
Esmolol
Class II Antiarrhythmic Short-acting Beta-1 blocker that can help control sympathetically driving ventricular tachycardia . Administered as a CRI on telemetry. Side effects: Negative inotropic effects may be too pronounced in some patients and cause cardiovascular collapse. Requires blood pressure monitoring.
70
Atenolol
Class II antiarrhythmic. The most common oral beta blocker in small animals. Relative beta 1 selectivity and long half-life compared to propranolol. Water soluble and eliminated by the kidney.
71
Metoprolol
Class II antiarrhythmic. Common oral beta blocker in small animals. Long half-life compared to propranolol. Metabolized and eliminated through the liver.
72
Class III Antiarrhythmic agents
Block the repolarization of I(k) resulting in prolongation of action potential durations and effective refractory period. Blocks rapid component of I(k) instead of the slow component -- therefore effects are accentuated at slower heart rates rather than at the problematic tachyarrhythmic rates. Puts patients at risk of early afterdepolarization (accounts of proarrhythmic effects of class III AA drugs) - risk is increased in patients with hypokalemia, bradycardia, intact females, increasing age, macrolide antibiotic therapy/other drug therapies
73
Amiodarone
Class III Antiarrhythmic Alpha and Beta blocking properties. Effects on sodium, potassium, and calcium channels. Broadest spectrum exhibiting properties of all 4 AA classes. Makes action potential durations more uniform throughout the myocardium and has the least reported proarrhythmic activity of any of the class III agents. Used for refractory tachyarrhythmias, both atrial and ventricular Significant side effects in dogs, including hepatopathy and anaphylaxis. Monitor heart rate, blood pressure and ECG with administer. Available as oral or injectable. Major drawback: associated with a host of multi-systemic adverse side effects that do not occur with sotalol. Adverse side effects (more common with higher maintenance doses): vomiting, anorexia, hepatopathies, thrombocytopenia Two brands: Cardarone IV, Nextarone
74
Cardarone IV
IV formulation of amiodarone Serious side effects attributed to vasoactive solvents in the formulation. Side effects include life-threatening hypotension, anaphylaxis, bradycardia, acute hepatic necrosis, and death.
75
Nexterone
Premixed aqueous solution of IV amiodarone. No adverse hemodynamic effects of other adverse cllinical effects in healthy research dogs.
76
Class IV antiarrhythmic agents
Calcium channel antagonist Slow AVN conduction and prolong the effective refractory period of nodal tissue Effects are more notable at faster stimulation rates and in depolarized fibers. Effective in slowing the ventricular response rate to atrial tachyarrhythmias and can prolong AVN's effective refractory period to terminate AVN-dependent tachyarrhythmia. It is mainly indicated to reduce the rate of arrhythmias passing through the AV node, such as supraventricular arrhythmias. Major negative inotropic effects due to interactions with calcium in the smooth muscles. Causes vasodilation Limit amount of calcium available in cardiac contractility. Diltiazem is the most widely used IV antiarrhythmic drug
77
Diltiazem
Class IV antiarrhythmic Calcium channel blocker. Minimal negative inotropic effects. Used in dogs to immediately terminate a severe AVN-dependent tachyarrhythmia or slow ventricular response rate to an atrial tachyarrhythmia. Adverse side effects: hypotension and bradyarrhythmia. Administer IV slowly over 2-3 minutes. Oral diltiazem administered TID.
78
Digoxin
Class V anti-arrhythmic (other) Effects occur indirectly through the autonomic nervous system by enhancing central and peripheral vagal tone. Used as an antiarrhythmic due to its ability to slow AV conduction time and have parasympathomimetic effects Treats SVT to slow AV nodal conduction and reduce ventricular rate Positive inotrope that will increase cardiac contractility in systolic disease The risk of toxicity manifests as neurological, GI, and cardiac involvement. Predisposed to toxicity if the patient has renal dysfunction, hypokalemia, elderly, chronic lung disease, hypothyroidism.
79
Magnesium Sulfate
1st line treatment for torsades de pointes Used to treat hypomagnesemia Administer slowly IV @ 30mg/kg over 5-10 minutes Adverse effects: CNS depress, weakness, bradycardia, hypotension, hypocalcemia and QT prolongation
80
Adenosine
Used in humans to terminate AVN dependent tachyarrhythmias. No study to date has shown effectiveness in dogs and cats.
81
Antiarrhythmic devices/procedures
Transvenous radiofrequency catheter ablation Permanent pacemaker implantation Implantable cardioverter defibrillators
82
Transverse radiofrequency catheter ablation
Identify reentrant circuit or automatic focus for ablation Deliver radiofrequency energy via electrode causing thermal desiccation of small volume tissue to interrupt tachycardia circuit
83
Permanent pacemaker implantation
Manage bradyarrhythmias
84
Implantable cardioverter defibrillators
experimental in dogs
85
Anticholinergics
class of drugs taht block the action of acetylcholine (ACh), a neurotransmitter that sends signals between cells that affect a bodily function. By blocking ACh at synapses in the central and peripheral nervous system, anticholinergics inhibit the parasympathetic nervous system.
86
Atropine
Anticholinergic inhibit acetylcholine at muscarinic receptors Clinical effects include increasing heart rate, resolving vagally mediated bradycardia, decreasing GI motility, pupillary dilation, bronchodilation, urinary retention and drying or secretion Most commonly used to treat vagal-mediated bradycardias and toxicities Able to pass the placental barrier.
87
Glycopyrrolate
Anticholinergic inhibit acetylcholine at muscarinic receptors Clinical effects include increasing heart rate, resolving vagally mediated bradycardia, decreasing GI motility, pupillary dilation, bronchodilation, urinary retention and drying or secretion Most commonly used to treat vagal-mediated bradycardias and toxicities Glycopyrrolate is associated with more stable cardiovascular system with fewer arrhythmias Glycopyrrolate has a stronger anti-saliva secretion effect than atropine It does not pass the placental barrier and, therefore, is the agent of choice for pregnant animals.
88
Diuretics (7 classes)
Loop diuretics Osmotic Diuretics Potassium sparing diuretics Thiazide diuretics Carbonic anhydrase inhibitors Aldosterone Antagonist Aquaretics (new)
89
Goals for diuretic therapy
Enhanced excretion of retained water, solutes and toxins Promote urine flow decrease urine concentration of solutes and toxins
90
Common indications for diuretic use
Oligoanuric acute renal failure decompensated kidney disease Congestive heart failure ascites from liver failure other fluid and electrolyte disorders
91
When it is justified to use diuretics to treat edema?
Only when fluid retention is caused by an increase in hydrostatic pressure. When vascular permeability is increased, further depletion of vascular volume with diuretics is rarely indicated and often detrimental
92
Adverse effect of exaggerated diuresis
May activate RAAS by reducing intravascular volume and ventricular filling and may subsequently decrease tissue perfusion. Therefore, diuresis requires therapeutic monitoring
93
Pathologic conditions that contribute to diuresis
pressure natriuresis osmotic diuresis
94
pressure natriuresis
A negative feedback in hypervolemic hypertensive states
95
Diuretics operating on which part of the nephron is most effective and why?
Diuretics at the loop of Henle are the most effective because of the large amount of filtrate delivered to this site and the lack of efficient distal reabsorption region.
96
What triggers an increase to antidiuretic production?
Elevated plasma osmolality hypovolemia hypotension (lesser extent) nausea increased concentration of angiotensin II
97
Osmotic diuresis
passive mechanism due to abnormal urine concentration of osmotically active solutes such as glucose and sodium
98
What is required for antidiuretic hormone to function?
functional renal tubular system medullary concentration gradient of sodium and urea functional ADH receptor system without any one of these factors will result in inappropriate diuresis
99
What may affect function of diuretics that work on proximal tubule?
Diuretics that work on proximal tubule can modulate a greater bulk of sodium, but their efficacy may be overcome by distal compensatory increases in sodium reabsorption.
100
What may limit efficacy of diuretics operating on distal tubule?
Diuretics operating on distal tubule may be limited by small amount of sodium reaching distal tubule
101
Osmotic Diuretics
hyperosmolality causes water shift from the intracellular fluid compartment to extracellular space, causing ECF expansion Used to contract ICF in cases with cerebral edema associated with an increase in ICF and elevated intracranial pressure Contraindicated for patients in or at risk of heart failure. Effective in patients with anuric or oliguric rental disease, cerebral edema and increased intraocular pressure eg. Mannitol
102
Mannitol
osmotically active non reabsorbed sugar alcohol filtered by the glomerulus; does not undergo tubular reabsorption, thereby increasing tubular flow rate and osmotic diuresis An increase in tubular flow rate reduces urea absorption, resulting in increased urinary clearance and serum urea concentration. Potential benefits of mannitol: Prostaglandin-induced renal vasodilation reduced tendency of erythrocytes to aggregate reduced renal vascular congestion reduced hypoxic cellular edema protection of mitochondrial function reduced oxidative damage renoprotectant when administered before toxic or ischemic event *No data supports above benefits in renal failure cases At high doses, mannitol can cause renal vasoconstriction and tubular vacuolization Use cautiously with oliguric animals to avoid volume overload, hyperosmolality and further renal damage.
103
Carbonic Anhydrase Inhibitors
Clinical application of carbonic anhydrase inhibitors - mainly used to treat elevated intraocular pressure in glaucoma. Work by suppressing the activity of carbonic anhydrase, an enzyme in red blood cells that converts carbon dioxide into carbonic acid and bicarbonate ions. CAIs can reduce secretion of H+ ions by the kidney tubule and can also impair the reabsorption of sodium, chloride and bicarbonate. eg. Acetazolamide Carbonic anhydrase also located on other organs. Blockade of ocular and brain CA decreases the production of aqueous humor and CSF. Blockade of red blood cell CA hampers carbon dioxide transport Gastric CA - minimally affected by inhibitors.
104
Acetazolamide
Carbonic anhydrase inhibitor Function: diuretic Inhibits mostly the type II (cytoplasmic) and IV(membrane) proximal tubular carbonic anhydrases, decreasing the reabsorption of sodium bicarbonate. Results in metabolic acidosis and natriuresis - minimal and self-limiting because progressively less bicarbonate is filtered as the proximal tubule becomes less responsive to carbonic anhydrase inhibition and the distal sodium reabsorption increases to compensate for the proximal losses.
105
Loop Diuretics
Binds to and inhibits Na+-K+-2Cl- cotransporters on the apical membrane of epithelial cells of the thick ascending loop of Henle. Inhibition of reabsorption of both Na and Cl, ions remain in the tubular lumen and water follows, resulting in diuresis and increased Na secretion ○ High sodium concentration later in the nephron results in increased sodium and potassium exchange, which leads to increased potassium secretion as well ○ Increased calcium secretion also occurs ○ Also believed to decrease renal vascular resistance and increase renal blood flow Prototypical loop diuretic: furosemide Torsemide
106
Furosemide
Loop diuretic Improves renal parenchymal oxygenation by decreasing the energy expenditure of the secondary active Na-K-2Cl transporter Mannitol + furosemide > synergistic in inducing diuresis in dogs with acute renal failure Relative short half-life: 1-1.5 hours in dogs > can result in intermittent rebound sodium retention with loss of efficacy. most commonly used in patients in heart failure.
107
Torsemide
potent loop diuretic of pyridine-sulfonylurea class longer half-life (8 hours) higher bioavailability (80%-100%) strong diuretic effect than furosemide Large scale study - effective in dogs with mitral valve disease, but high rate of renal adverse events. Additional benefits observed in other species: vasodilation, improved cardiac function, reduction of myocardial remodeling, mineralocorticoid-receptor blockade with anti-aldosterone effect - has not been shown in small animals
108
Thiazide diuretics
exert their action by inhibiting the NaCl cotransporter on distal tubule. Mainly used for anticalciuretic properties to prevent calcium-containing uroliths Managing CHF in conjunction with other diuretics treating ascites associated with right-sided heart failure also used for treating polyuria of diabetes insipidus by inducing a mild hypovolemia and increasing proximal sodium conservation. eg. Hydrochlorothiazide
109
Aldosterone Antagonist
Antagonize aldosterone by binding to its receptor in the late distal tubule and the collecting duct increases sodium, calcium and water excretion and decreases potassium loss e.g. Spironolactone and eplerenone
110
When to suspect hyperaldosteronism
concurrent hypernatremia, severe hypokalemia
111
Spironolactone
Aldosterone antagonist potassium sparing diuretic Best used in cases of hyperaldosteronism Main clinical applications in liver and heart failure. Also used as an antihypertensive in hyperaldosteron cases. Usually, it is in combination with a more efficient loop diuretic. Also seems to have a positive effect on myocardial remodeling and the reduction of cardiac fibrosis Commonly added to other diuretics to reduce their potassium-wasting effects Main adverse effect: development of hyperkalemia
112
potassium-sparing diuretics
Inhibit sodium reabsorption in the distal tubule and the collecting duct; suppressing the driving force for potassium secretion. Only weak diuretic and natriuretic properties Mostly used to counterbalance potassium-wasting effects of proximal diuretics. e.g. Amiloride and triamterene
113
Aquaretics
New class of diuretics that antagonize the vasopressin V2 receptor in the kidney and promote solute-free water clearance Vaptans - vasopressin receptor antagonist Clinical use: free water rention in hypervolemic hyponatremia or normovolemic hyponatremic drugs: conivaptan, tolvaptan and mozavaptan Not used in small animals
114
Pimobendan
Function: positive inotropic and vasodilatory effects Phosphodiesterase III inhibitor Calcium sensitization Used to treat congestive heart failure
115
Mechanism of Pimobendan via calcium sensitization
increase contractility via increasing binding affinity to the regulatory site on troponin C for calcium sensitizes the myocyte contractile apparatus to calcium without increasing the amount of calcium within the cell. Pimobendan is not dependent on catecholamines
116
Mechanism of pimobendan via phosphodiesterase III inhibition
increase contractility by increasing intracellular calcium levels. PDE III inhibition increases cyclic adenosine monophosphate (cAMP), which in turn increases cAMP-dependent protein kinase. Increase in calcium sequestration during diastole and increase in calcium influx during systole - both contribute to positive inotropy PDE III and PDE V are found in vascular smooth muscle. Inhibition of PDE III and PDE V increases intracellular cAMP and cGMP - which facilitates calcium update through intracellular storage sites. Results in reduction of available calcium for contraction > greater vascular smooth muscle relaxation.
117
Elimination of Pimobendan
undergoes hepatic demethylation
118
bioavailability and duration of affect of Pimobendan
Pimobendan is highly protein bound with greater than 90% bioavailability. Maximal cardiac effects at 2-4 hours following oral administration and persists up to 8 hours.
119
Clinical use of pimobendan
FDA approved to treat CHF with myxomatous mitral valve degeneration or DCM
120
Adverse effects of pimobendan
generally well tolerated but may cause GI upset - inappetence, vomiting, diarrhea and lethargy
121
Anti-hypertensives (7 mechanisms of action)
Angiotensin-converting enzyme inhibitor Angiotensin receptor blocker aldosterone antagonist calcium channel blocker alpha 1 antagonist beta antagonist arteriolar vasodilator
122
Angiotensin-converting enzyme inhibitor (ACE inhibitor)
Family of drugs designed to disrupt the renin-angiotensin-aldosterone system (RAAS). Medications function by inhibiting the conversion of angiotensin I to angiotensin II. ACE inhibitors can decrease proteinuria promote vasodilation, venodilation and reduction in plasma volume with reduction in systolic blood pressure ACE inhibitors can cause decreased metabolism of vasodilatory agent bradykinin --> further reduction in vascular tone Clinical application of ACE inhibitors where systemic hypertension is caused by known or suspected increase in RAAS - most commonly related to chronic kidney disease and or glomerular disease. Most commonly considered 1st line treatment for dogs (not cats). Generally well tolerated. Biggest concern: potential to worsen glomerular filtration rate and renal function through preferential dilation of the efferent arteriole (thereby reducing glomerular filtration pressure) e.g. Enalapril, benazepril, lisinopril
123
Enalapril
Angiotensin Converting Enzyme Inhibitor
124
Benazepril
Angiotensin Converting Enzyme Inhibitor
125
Lisinopril
Angiotensin Converting Enzyme Inhibitor
126
Angiotensin receptor blockers (ARBs)
Class of drugs that block angiotensin II from its receptor. **Does not affect the metabolism of bradykinin** ARBs can decrease proteinuria promote vasodilation, vasodilation and reduction in plasma volume with a reduction in systolic blood pressure Side effects: similar side effects as ACEi; avoided or cautiously used in patients with severe dehydration or azotemia. e.g. Telmisartan, losartan
127
Telmisartan
Angiotensin receptor blocker
128
Calcium channel blockers
decrease calcium influx into cardiac tissues (antiarrhythmic properties) and vascular smooth muscles (antihypertensive properties) May cause reflex bradycardia Other side effects could include weakness, lethargy, decreased appetite CCBs promote preferential afferent arteriolar dilation over the efferent arteriole, which increases intraglomerular pressure, which could damage the glomerulus and worsen proteinuria.
129
Amlodipine
Belongs to the dihydropyridines family Calcium channel blocker Relative selectivity for vascular smooth muscles so promotes vasorelaxation and reduces systemic vascular resistance An associated decrease in blood pressure may trigger reflex tachycardia. First-line antihypertensive of choice for managing SHT in cats
130
Phentolamine
Alpha 1 adrenergic antagonist used in hypertensive crisis, specifically as rescue therapy during pheochromocytoma surgery
131
phenoxybenzamine
Alpha 1 adrenergic antagonist commonly used to stabilize patients with pheochromocytoma prior to surgical intervention
132
Vasopressor
Any drug specifically used to cause constriction to blood vessels increase cardiac afterload, produce vasoconstriction, increase vasomotor tone and systemic vascular resistance most common pathway is alpha 1 adrenergic agonism
133
positive inotrope
Any drug specifically used to increase cardiac contractility most common pathway to achieve this is beta 1 adrenergic agonistm
134
Negative inotrope
decrease cardiac contractility
135
Dopamine
Catecholamine and sympathomimetic Primary receptors: dopaminergic, beta-1 and alpha 1 adrenergic agonist different doses = different effects Low range - stimulate urine production in oliguiric or anuric AKI Intermediate range: predominantly positive inotropic effects High doses: vasoconstriction/increase in vascular resistance Effects: increases renal blood flow improves inotropy increases heart rate increases systemic vascular resistance increases blood pressure increases cardiac out put Deliver as a CRI Side effect: arrhythmias, tachycardia, hypertension Continuous ECG, BP monitoring recommended
136
Dobutamine
Sympathomimetic receptors: Beta-1 and Adrenergic-2 agonist Effects: improves inotropy +/- increase in heart rate Increase in cardiac output +/- increase in blood pressure decrease systemic vascular resistance Deliver as a CRI Side effects: arrhythmias, tachycardia, hypertension, bradycardia Monitoring: ECG/BP continuous
137
Norepinephrine
catecholamine and sympathomimetic Receptors: Alpha-1 and beta 1 adrenergic agonist Effects: increase in inotropy decrease in heart rate increase in systemic vascular resistance increase in blood pressure Deliver as a CRI Side effects: arrhythmias, hypertension, bradycardia, excessive vasoconstriction
138
Epinephrine
Catecholamine Receptors: alpha 1 and beta 1 adrenergic agonist Lower doses have predominantly beta agonist effect: vasodilation, bronchodilation, increased cardiac contractility and cardiac output, increased heart rate higher doses: more alpha 1 adrenergic effects: vasoconstriction Used to treat anaphylaxis Side effects: arrhythmia Monitoring: continuous ECG/BP Deliver as IV bolus, CRI, IM or intratracheally
139
Phenylephrine
sympathomimetic receptor: alpha-1 adrenergic agonist Effects: decrease in heart rate increase in systemic vascular resistance (marked vasoconstriction) increase in blood pressure May improve blood pressure, but the increase in cardiac afterload may decrease stroke volume and cardiac output Deliver as a bolus or CRI Side effects: arrhythmia, hypertension, bradycardia, excessive vasoconstriction
140
Ephedrine
Sympathomimetic receptors: beta-1 agonist, and alpha 1 adrenergic agonist effects: increase inotropy increase in blood pressure increase in cardiac output +/- Heart rate increase in systemic vascular resistance deliver as a bolus (short duration of effect) or CRI Side Effects: arrhythmias, tachyphylaxis (reduced sensitivity after repeated administration), hypertension, bradycardia, tachycardia
141
Vasopressin receptors? Effects? Delivery method? side effects?
Non-adrenergic hormone AKA anti-diuretic hormone receptors: V1 vasopressin Agonist effects: increase systemic vascular resistance increase blood pressure Increase in cardiac afterload may decrease stroke volume and cardiac output, resulting in decrease oxygen delivery to tissue Alternative or conjunctive therapy to epinephrine in CPCR More effective than epinephrine when patient in acidosis. deliver as a bolus or CRI Side effects: arrhythmias, hypertension, bradycardia, excessive vasoconstriction
142
What stimulates the release of vasopressin? by which mechanisms?
- increases in plasma osmolality - central chemoreceptors detect systemic osmolality. Peripheral chemoreceptors in mesenteric and portal veins detect changes in osmolality of ingesta. Afferent impulses ascend via vagus nerve to stimulate vasopressin release. Plasma tonicity sened by hypothalamus to stimulate more vasopressin release. - decreases in blood pressure - shifts osmolality. Baroreceptors in left atrium, aortic arch and carotid sinus sense drops in blood pressure and circulating blood volume. Allows for release of disinhibition of vasopressin release. - drop in circulating blood volume
143
Vasopressin release can be inhibited by which drugs?
glucocorticoids low dose opioids atrial natriuretic factor GABA neurotransmitter
144
Vasopressin receptors: V1 receptor location and mechanism of action
found primarily on smooth muscle cells Activation of voltage gated calcium channels, increases intracellular calcium levels allowing for vasoconstriction. V1-R in platelets - facilitates thrombosis because of intracellular calcium V1-R in kidneys decrease blood flow to inner medulla and limit anti-diuretic effects; selective cause contraction of efferent arterials to increase GFR There are species variations in V1R locations.
145
Vasopressin receptors: V2 receptor location and mechanism of action
Found primarily on basolateral membrane of distal tubule and principle cells of cortical and medullary rental collecting duct triggers fusion of aquaporins with plasma membrane of collecting duct --> increasing water absorption. stimulates release of platelets from bone marrow and enhances release of Von Willebrand's factor and Factor VIII from endothelial cells
146
Role of vasopressin in homeostasis
regulating fast shuttling of aquaporin-2 to cell surface stimulates synthesis of RNA encoding aquaporin 2 hereditary nephrogenic diabetes insipidus have V2-R gene mutations
147
Vasopressin metabolism and excretion
half life is 24 minutes cleared by renal excretion and metabolized by tissue peptidases
148
Adverse effects of Vasopressin
contraction of bladder and gallbladder smooth muscles increase peristalsis decrease in gastric secretions increase in GI sphincter pressure Local irritation at injection site. If extravasated, may cause skin necrosis May increase liver enzymes and bilirubin levels decrease platelet count hyponatremia anaphylaxis/urticaria bronchospams abdominal pain hematuria water intoxication reported with high dose treatment of diabetes
149
Terlipressin
selective for V1R prolong duration - 6 hours half life Used to manage hemorrhagic gastroenteritis increase adverse effects - peripheral cyanosis/ischemia (use with caution)
150
Selepressin
V1R agonist found to reduce risk of coronary ischemia less adverse effects on mesenteric blood flow and gastric mucosal perfusion effective substitute for maintaining MAP, reducing vascular leak, edema formation and shortening duration of shock. Comparative study with norepi -> no improved outcome
151
Desmopressin acetate
synthetic vasopressin intranasal and injectable form binds primarily to V2R more potent antidiuretic and procoagulant
152
Streptococcus
gram-positive cocci arranged in chains
153
Group A streptococci
It can cause pharyngitis, glomerulonephritis, and rheumatic fever in humans. It rarely causes illness in dogs and cats, although dogs can carry the organisms.
154
Group C streptococci
rare causes of illness in healthy dogs and cats
155
Group G
common resident microflora and are the cause of most streptococcal infections in dogs and cats. Streptococcus canis is the most common.
156
Streptococcus canis
The main source of infection in anal mucosa in dogs. May be found in cats in abscesses, pyelonephritis, sinusitis, arthritis, metritis or mastitis In dogs, it may be the cause of nonspecific infections including wounds, mammary tissues, urogenital tract, skin and ear canal. May cause toxic shock syndrome in dogs. Tx: Penicillin-G and ampicillin are effective for most infections
157
Group D streptococci
Enterococcal Commensal bacteria that inhabit the alimentary tract of humans and animals Most commonly see in post op wounds and urogenital infections.
158
Staphylococcal Infection
Gram positive bacteria, developing resistance to antimicrobials. cephalosporins, penicillins and fluoroquinolones decreasing in effectivness.
159
Gram Negative
significant cause of morbidity and mortality in critically ill patients
160
Lipid A
known to be toxic Induces proinflammatory responses and endothelial dysfunction harmful effects of endotoxin include vasodilation, enhanced vascular permeability, tissue destruction, and activation of coagulation pathways
161
Apomorphine
Stimulates the chemoreceptor trigger zone to induce emesis as a non-selective dopamine agonist Side effects: Failure to produce emesis, refractory vomiting, nausea, sedation Adverse sedative effects can be reversed with an opioid agonist such as naloxone
162
Alpha-2 Adrenergic Agonist
Induces emesis Thought to occur through the stimulation of the chemoreceptor trigger zone at least in part through the area of postrema of the medulla oblongata Concerns include sedation, hyperglycemia, bradycardia, increased systemic vascular resistance, and increased cardiac afterload. Drug: dexmeditomidine
163
Xylazine
Alpha-2 adrenergic agonist
164
Dexmeditomidine
Alpha-2 adrenergic agonist
165
Peripheral acting emetics
most common include hydrogen peroxide, syrup of ipecac, and salt paste syrup of ipecac no longer used due to potential for abuse and fatal cardiac arrhythmia. Salt paste no longer clinically used due to risk of hypernatremia and questionable efficacy Hydrogen peroxides: irritate oral, esophageal and gastric mucosa
166
Phenothiazine Derivatives
Acepromazine, chlorpromazine and prochlorperazine Reduce emesis through blockade of dopamine receptors in CRTZ and emetic centers No longer used because of potential side effects and availability of more effective agents Produce an alpha-1 adrenergic antagonist which causes systemic vascular resistance and vasodilation; can result in hypotension
167
Metoclopramide
Prokinetic Dopamine and serotonin antagonist and cholinergic agonist Increases lower esophageal sphincter tone, facilitates gastric emptying short half-life, thus usually prescribed as a CRI contraindication: mechanical obstructions in the GI tract and intussusceptions
168
Ondansetron
Serotonin (5-HT3) Antagonist Block serotonin receptors in the CRTZ and peripherally Appear to be more effective than phenothiazine and metoclopramide Side effects are rare
169
Maropitant
Neurokinin-1 (NK) antagonist Blocks substance P at vomiting center in the brain
170
Proton Pump Inhibitors
Omeprazole, pantoprazole, esomeprazole Inhibits Na/K ATPase pump activity Recommended treatment for acid suppression; controls proton deposition in the gastric lumen and hydrochloric acid secretion
171
H2 Histageneric Antagonist
Famotidine, ranitidine, cimetidine H2 blockers Specific antihistamines that reduce the action of histamine at histamine receptors on gastric parietal cells; reduce stomach acid
172
Sucralfate
Sucrose sulfate-aluminum complex Binds to locally injured GI lining and creates a physical barrier Promotes bicarb production and may increase production of prostaglandin E2 Commonly used to treat GI or duodenal ulcers Can also be beneficial in esophageal strictures
173
Misoprostol
Synthetic prostaglandin E1 analogue It improves gastric blood flow, decreases gastric acid production, increases mucus production and bicarb secretion, and promotes cell turnover. Specifically used to help prevent NSAID-induced GI injury and ulceration Also has effects on myometrial contraction Wear gloves when handling
174
Beta-2 adrenergic agonist
Bronchodilators and enhance mucus clearance via mucociliary system Relaxes smooth muscle in respiratory passageways May also cause vasodilation in muscles. Commonly used to trat asthma in cats, chronic bronchitis in dogs or hyperkalemia drugs: terbutaline, albuterol, salmeterol Most common side effects: tachycardia, increased cardiac contractility and arrhythmia
175
Terbutaline
beta-2 adrenergic agonist Bronchodilator Commonly used to treat asthma in cats, chronic bronchitis in dogs or hyperkalemia Administered orally or parenterally Common side effects are tachycardia, increased cardiac contractility and arrhythmia
176
Albuterol
beta-2 adrenergic agonist Bronchodilator administered via inhaler Common side effects are tachycardia, increased cardiac contractility and arrhythmia I.e. albuterol toxicity
177
Methylxanthines
bronchodilator Inhibit phosphodiesterase and blocking adenosine believed to inhibit leukotriene synthesis and reduce inflammation Narrow therapeutic range Occasionally used to treat pulmonary hypertension and tracheal collapse. adverse effects are tachycardia, arrhythmia and GI signs examples of Methylxanthines: Caffeine and theobromine - toxic to animals
178
Diphenhydramine
Antihistamine Inverse agonist of H1 histagenergic receptor (produces opposite effect of histamine since its an inverse agonist) influences muscarinic acetylcholine receptors, sodium channels and potentially reuptake of serotonin Predominately used for: - reducing signs of acute allergic reactions - treat increase capillary permeability secondary to histamine release. - reducing symptoms of histamine release from Mast cell tumors. - crosses the blood brain barrier --> affect CNS; cause sedation or excitement (rare in dogs and cats) Do not administer SQ because of irritating effects.
179
Meclizine
antihistamine Used for patients with vestibular disease Antiemetic and motion sickness
180
Cyproheptadine
antihistamine serotonin agonist Used as a mild appetite stimulant Can also be used to treat serotonin syndrome --> evidence to support efficacy is limited
181
Mirtazapine
antihistamine Has an effect on serotonin, adrenergic, dopamine and muscarinic receptors weak appetite stimulant and antiemetic
182
Asprin
nonsteroidal anti-inflammatory drug blocks platelet cyclo-oxygenase (COX)1 which causes inhibition of thromboxane A2 (TXA2) Effect is irreversible Primarily used to treat hypercoagulable states or states of increased platelet reactivity
183
Clopidogrel
Thienopyridine class drug Blocks adenosine diphosphate (ADP) induced platelet aggregate through binding the platelet P2Y12 receptor Primarily used to treat hypercoagulable states or states of increased platelet reactivity Does not remove already formed blood clots
184
Heparins
Naturally occurring - stored within mast cells and released into vasculature at sites of tissue injury Drug - Unfractionated heparin: heparin sulfate can be reversed using protamine sulfate Drug - low molecular weight heparins: Dalteparin and enoxaparin Does not dissolve preexisting blood clots
185
Enoxaparin
Low molecular heparin Associated with fewer bleeding events, more predictable absorption and can be given less frequently than UFH Inhibits factor Xa Incompletely reversed by protamine sulfate
186
Heparin sulfate
Unfractionated heparin Binds to antithrombin and inhibits factors IIA, IXa, Xs, XIa, and XIIa can be reversed using protamine sulfate
187
Direct Factor Xa Inhibitors
Rivaroxaban and apixaban Does not require antithrombin for factor Xa inhibition and clinical effects Does not dissolve blood clots that have already formed
188
Rivaroxaban
Trade name: Xarelto Direct Factor Xa inhibitor Oral anticoagulant used to prevent or treat thrombosis in high risk patients Contraindicated in patient with uncontrolled pathologic bleeding, severe hepatic disease, hepatic disease associated with coagulopathy or with significant renal impairment
189
Thombolytics
Drugs: streptokinase, urokinase, tissue plasma activator (t-PA) Not widespread in vetmed Should be administered as early as possible to be most effective contraindicated or inappropriate in situations of known coagulopathy, states of active bleeding, cardiac thrombi, neoplasia that invades the vasculature and infective endocarditis Complication associated with thrombolytic agents: Bleeding
190
What are the two pathways in the arachidonic acid cascade?
1) 5-lipoxygenase (LOX) 2) Cyclo-oxygenase (COX)
191
What is the first thing that occurs when tissue is injured in the process of inlammation?
Arachidonic acid is released from the cell membranes, triggered by phospholipase A2
192
What occurs during LOX?
Arachidonic acid is metabolized into leukotrienes by LOX
193
What occurs during the Cox pathway?
arachidonic acid is metabolized into prostaglandins, prostacyclin and thromboxanes by COX
194
Two isoenzymes of COX
COX 1 and COX2
195
COX 1
Primarily responsible for basal prostaglandin production for normal homeostatic processes within the body, including gastric mucus production, platelet function, and, indirectly, hemostasis.
196
COX 2
found at sites of inflammation and some basal production of constitutive prostaglandins. Ideally, selective inhibition of prostaglandins produced primarily by COX-2, however currently there are no pure COX2 inhibitors.
197
Arachidonic Acid
Present in phospholipid portion of plasma membrane. It is an inflammatory mediator which causes vasodilation and vasoconstriction. Inflammation = vasodilation blood coagulation = vasoconstriction Phospholipase A2 releases Arachidonic Acid. Arachidonic Acid can then be broken down to prostaglandins or the leukotriens by COX or LOX respectively.
198
What inhibits phospholipase A2?
steroids Therefore steroids are anti-inflammatory
199
NSAIDs function and adverse effects
NSAIDs inhibit COX enzyme, which inhibits formation of prostaglandins. NSAIDs are metabolized by the liver and excreted by the kidneys. Give with food. Adverse side effects: Because prostaglandins play a role in maintaining GI mucosal integrity, some of the side effects of NSAIDs are gastroenteritis, ulceration, and potentially GI perforation. Use cautiously in patients with hypotension, hypovolemia, pre-existing renal disease (due to increased potential for renal vascular vasoconstriction which could lead to worsening of renal insufficiency) use with caution perioperatively because of decreased platelet function --> may increase risk of operatie hemorrhage.
200
leukotrienes
Produced when lipoxygenase acts on arachidonic acid. Lipid-like bronchoconstrictors that are released during the inflammatory response. Asthma is treated with inhaled and oral medications that include beta-2 adrenergic agonist anti-inflammatory drugs and leukotriene antagonist
201
Prostaglandins
Produced when cyclooxygenase (COX) acts on arachidonic acid. Many functions including: Inflammation, Reproduction, gastric secretions, blood clotting Two types of prostaglandins depending on tissue type. Location: Platelets --> Thromboxane Location: Endothelium --> Prostacyclin Thromboxane -->vasoconstriction +bronchoconstrictor = procoagulation Prostacyclin --> vasodilation + prevent platelet aggregation = anticoagulation **Prostaglandins protect GI mucosa from environment of stomach**
202
Thromboxane (3 functions)
Vasoconstrictor increases platelet aggregation bronchoconstrictor
203
Prostacyclin
"keeps blood cyclin" 1. vasodilator 2. decreases platelet aggregation
204
Prostaglandin (PGE2) functions
1. Promote fever 2. promotes pain
205
Steroids
Inhibits Arachidonic acid prostaglandins and leukotriens
206
What promotes Phospholipase A2?
tissue injury thrombin bradykinin angiotensin II (stimulates vasoconstriction) epinephrine (stimulates vasoconstriction)
207
meloxicam
NSAID
208
carprofen
Rimadyl, Carprovet, Truprofen NSAID
209
firocoxib
Previcox or Equioxx NSAID
210
deracoxib
Deramaxx NSAID
211
grapiprant
Galliprant NSAID
212
robenacoxib
Onsior NSAID
213
Endogenous steroids are produced by which organ?
Adrenal gland, gonads and placenta
214
What are the two classes of corticosteroids?
Glucocorticoids and Mineralcorticoids
215
Function of Gluococorticoids
Increase carb, protein and fat metabolism growth (specifically in utero) increase contractile activity of left ventricle signal kidneys to reabsorb sodium inhibit activity of cells that are used to promote connective tissue production alter turnover of bone stop GI from absorbing calcium and promote calcium excretion from kidney Inhibit formation of prostaglandins and bradykinins -> inhibit inflammation suppress white blood cells (lymphocytes and eosinophils)
216
Antimicrobial stewardship and deescalation (3 key components)
1. optimize antimicrobial use 2. minimize the duration of prescription 3. Re-escalating antimicrobial therapy when culture and susceptibility results have returned
217
Exceptions to 7 day administration of antimicrobials
1. endocarditis 2. prosthetic implants 3. persistent neutropenia
218
Time dependent antimicrobials efficacy
only efficacious when [drug] in plasma is above the MINIMUM INHIBITORY CONCENTRATION (MIC) for that pathogens. Note: in critically ill patients, ft>MIC may be 100%
219
ft>MIC
percentage of time drug concentration is above the minimum inhibitory concentration.
220
Concentration dependent antimicrobials
usually bind irreversibly to their target their efficacy is usually predicted by comparing the maximum concentration (Cmax) to the MIC) Critical illness Cmax:MIC should be >8
221
How might fluid overload affect antimicrobial pharmacokinetics?
Depending on if the antimicrobial is hydrophilic or lipophilic Volume of distribution of the antimicrobial will be affected e.g. If the antimicrobial is hydrophilic, the net effect of volume distribution is higher, decreasing [antimicrobial] in plasma --> decreasing [antimicrobial] in target tissue
222
Effects of AKI on antimicrobial elimination and considerations
AKI --> elimination via kidney is decreased therefore fT>MIC is increased. However, must consider risk of toxicity is increased due to drug accumulation
223
Effects of augmented renal clearance (ARC) on antimicrobial elimination
Augmented renal clearance --> increased removal of substrate by the kidneys Antimicrobials may remain at subtherapeutic levels resulting in worsening patient outcomes Incidence not studied in VetMed.
224
Effects of hepatic dysfunction on antimicrobial administration
Antimicrobial clearance may be decreased for hepatically metabolized drugs. (Usually takes reduction of 90% of liver) --> therefore patients in fulminant liver failure = consider dose reduction Generally no change needed if biochem panel shows hepatic dysfunction.
225
What are the 4 classes of Beta-lactams?
Penicillins cephalosporin carbapenam monobactam
226
Beta-lactams distinguishing feature and mechanism of action
beta lactam ring effects exerted by disrupting the synthesis of the cell wall during bacterial replication by binding to the "penicillin-binding proteins" (PBP) when beta lactam ring binds to PBP --> results in degradation of cell wall and imparis synthesis of new cell wall leaving bacteria exposed to local environment and resulting in bacterial lysis Beta lactams are bactericidal
227
Four factors that influence resistance to beta lactams
alterations to PBP development of antimicrobial efflux pumps changes to porins in bacterial cell wall inactivation by beta lactamases --> can be acquired or intrinsic resistance
228
Penicillins
Beta-lactam Gram positive and anaerobic coverage Minimal gram negative coverage Able to kill enteric flora which can cause vomiting and diarrhea. C
229
Penicillin excretion
Excreted unchanged in urine highly effective in UTI
230
Penicillin Drugs
benzylpenicillin (Pen-G), phenoxymethylpenicillin (penicillin V), procaine penicillin, benzathine penicillin (pen B)
231
Cloxacillin, methicillin, oxacillin
Beta-lactamase resistant Most effective against gram positive aerobes and anaerobes.
232
Cephalosporin
Beta-lactam 5 generations: grouped into generations based on their relative spectrum of activation lower the generation, the better gram positive spectrum the higher the generation, the better gram negative coverage more stable against beta lactamases than penicillins
233
1st generation Cephalosporin
beta-lactam effective against variety of gram positive limited activity against anaerobic bacteria. drugs: cefazolin, cephalexin, cefadroxil
234
2nd generation Cephalosporins
moderate gram positive and gram negative increase spectrum against anaerobes drugs: cefoxitan, cefotetan, cefuroxime
235
3rd generation cephalosporins
Broad spectrum activity with resistance to many beta lactamases relies on normal plasma albumin for effective therapeutic serum levels Good penetration of CSF drugs: ceftiofur, cefotaxime, ceftazidime, cefovecin(Convenia - 1 injection for 14 days), cefpodoxime (only drug in this gen available as oral medication)
236
4th generation cephalosporin
excellent activity against enteric organisms drugs: cefepime, cefpirome and cefquinome
237
5th generation cephalosproin
only 1 drug: ceftaroline spectrum of action similar to 3rd gen - good gram positive coverage retains efficacy to Staphylococcus spp. that are resistant to methicillin
238
Monobactams
Drug: Aztreonam Gram Negative coverage Not used much in vetmed
239
Carbapenems
broad spectrum resistant to many beta lactamases considered top tier antimicrobial goup and should not be used empirically Drugs: imipenem, doripenem, ertapenem and meropenem
240
Imipenem
Carbapenem beta lactam antimicrobial nephrotoxic - drug degrades in renal tubule by kidney enzyme dehydropeptidase 1 Administer with Cilastatin to prevent degradation associated with seizures in humans
241
Meropenem
Carbapenem beta lactam antimicrobial not nephrotoxic
242
Beta-lactamase inhibitors (3)
clavulanic acid sulbactam tazobactam bind irreversibly to beta lactamases so when administered with a beta lactam, the beta lactam can bind to bacterial PBP.
243
Beta lactam adverse effects
Toxicity to beta lactam group considered very low. Potential adverse reactions: Type 1 hypersensitivity from urticaria to anaphylaxis - frequency unknown in small animals (occurs in 0.7%-10% of people receiving penicillin Type 2 hypersensitivity can also occur -- hemolytic anemia, thrombocytopenia and neutropenia reported Type 4 reactions usually manifest as cutaneous disease Can rigger immune-mediated reactions such as IMHA Can kill neric flora which cause nausea, vomiting, diarrhea High doses can result in seizures and other neurologic diseases (more likely if brain diseases already present)
244
Aminoglycosides
Antimicrobial used to treat gram negative infections Rely on aerobic bacterial metabolism parenteral administration only requires monitoring of renal function Exhibit synergistic bactericidal effects when administered in combination with beta lactams
245
Aminoglycosides mechanism of action (3 stage model theory)
Inhibit bacterial protein synthesis by binding to ribosome resulting in faulty protein. further synthesis increases aminoglycoside uptake by the cell which eventually leads to complete cessation of ribosomal activity. Stage 1: outer bacterial lipopolysaccharide membranes are negatively charged while aminoglycoside is positively charged. Ionic binding allows aminoglycoside entry into cell and increase cell wall permeability Stage 2: Energy dependent phase Faulty protein synthesis inserted into cytoplasmic membrane of bacteria allowing for more aminoglycoside entry (slow process and relies on ATP hydrolysis --> therefore reduced activity in anaerobic conditions). This stage can be blocked by inhibitors of oxidative phosphorylation or electron transport Stage 3: Aminoglycoside accumulate quickly after nonspecific membrane channels inserted --> increasing rate of mistranslation of protein synthesis
246
3 mechanisms of actions to aminoglycoside resistance + intrinsic resistance
1. enzymatic mutation of aminoglycoside molecules 2. target modification in ribosomal 30s subunit structure 3. increase in aminoglycoside efflux 4. intrinsic resistance to anaerobes
247
Aminoglycoside absorption, distribution, metabolism and elimination
Absorption: water soluble; poorly absorbed from GI tract therefore must be administered parenterally Distribution: primarily extravascular - can reach bone, synovial fluids, peritoneal fluid (especially if inflammation present). Distribution to bronchial secretions is good. Does not penetrate cell membranes well because of positive charge. Not recommended for CNS, eyes or prostate. Elimination: primarily through kidneys unchanged by glomerular filtration.
248
Aminoglycosides Adverse Effects
Aminoglycosides readily taken up by cells in proximal tubules and in ears 5-15% will suffer aminoglycoside induced nephrotoxicity (excreted through kidneys) Nephrotoxicity: dose dependent majority of aminoglycoside is excreted but small amount is absorbed by renal tubules Necrotic cells slough into tubular lumen which can result in obstruction Underlying renal dysfunction predisposes patient to aminoglycoside induced nephrotoxicity Often damage is reversible if caught early. Ototoxicity: hair cells update drug resulting in cell death and inflammation dose and duration dependent Ototoxicity is not reversible Neuromuscular blockade Rarely reported, but can be severe enough to cause respiratory depression @ high doses - calcium release impaired at level of neuromuscular junction --> hypocalcemia. Concurrent use of neuromuscular blockade medications or myorelaxants may augment effets.
249
Aminoglycoside drugs
Amikacin Gentamicin sulfate Tobramycin sulfate neomycin
250
Amikacin
aminoglycoside Monitor for casts in urine and increases in BUN/Creat dosage may need to be adjusted in critically ill patients can be administered IV, IM, SQ q 24 hrs
251
Gentamicin Sulfate
Aminoglycoside Monitor for casts in urine and increases in BUN/Creat Can be administered IV, IM, SQ, q 24 hours
252
Tobramycin sulfate
Amino glycoside Monitor for casts in urine and increases in BUN/Creat Can be administered IV, IM, SQ q24 hours
253
Neomycin
Aminoglycoside Used to treat hepatic encephalopathy Minimal GI absorption administer PO q 6-12 hrs
254
Fluoroquinolones Mechanism of action effectiveness and resistance
synthetic antimicrobials Inhibit bacterial DNA gyrase which prevents bacterial DNA synthesis, replication and division, resulting in cell death Bactericidal Widest spectrum against gram-negative bacteria Incomplete effectiveness against gram-positive and anaerobic bacteria RESISTANCE TO FLUOROQUINOLONES CAN DEVELOP DURING THE COURSE OF THE TREATMENT
255
Fluroquinolones metabolism and elimination
hepatic metabolism and excreted in bile +/- urine either unchanged or as metabolites Most are eliminated by the kidneys Half-life depends on renal elimination and dose
256
Resistance to fluroquinolones
increasing rate of resistance attributed to widespread use of fluoroquinolones Use of fluoroquinolones can lead to development of resistance to other antimicrobial classes Fluoroquinolones should not be used as 1st line treatment. (exception - pyelonephritis, lower respiratory tract infections, bacterial prostatitis, hepatobiliary infections).
257
Adverse effects of fluoroquinolones
GI upset: V/D, nausea, abdominal cramping Neurologic: rapid administration risk CNS adverse effects including seizures It may lower the seizure threshold; therefore, do not use or use it with extreme caution in patients with seizure disorders. Juveniles: cartilage defects - not recommended in growing animals retinopathy: irreversible blindness in cats Rapid IV administration may result in histamine release in dogs Can chelate with positively charged ions - contains beta-keto acid group that can bind to and chelate with positively charged ions; most profoundly seen with aluminum and copper, but can also happen with magnesium and calcium Cardiovascular signs can result in hypotension, bradycardia, prolonged QT Rare reports of fluoroquinolones used in patients with necrotizing fasciitis resulted in activating bacteriophage, rapid bacterial cell lysis, and release of bacteriophage superantigen and the potential sequelae of toxic shock syndrome.
258
Enrofloxacin
2nd fluoroquinolone only one available as injectable for dogs and cats generally safe, though adverse effects can be permanent Adverse effects can include: - blindness in cats - cartilage defects in juvenile animals Max dose in cats if 5mg/kg q24hrs primary metabolite of enrofloxacin is ciprofloxacin.
259
Marbofloxacin
2nd gen fluroquinolone longest post-antibiotic effect and half-life No clinical trials support the translation of long half-life to superior antimicrobial efficacy.
260
Pradofloxacine
3rd gen fluoroquinolone Labeled for use in cats 12 weeks +, off-label for dogs (use in dogs associated with bone marrow suppression) broad spectrum activity including many anaerobic bacteria High potency with lower MIC values when compared with other fluoroquinolones
261
Ciprofloxacin
2nd gen fluoroquinolone not labeled for veterinary use Significantly higher doses needed in dogs than in humans and even so does not always achieve desired serum levels
262
Moxifloxacin
4th gen fluoroquinolones improved activity against gram-positive and gram-negative only used in human medicine
263
Metronidazole drug class Indications and mechanism of action
nitromidazole antimicrobial Indicated to treat most gram-positive anaerobic and all gram negative anaerobic organisms At higher dosages - effective against protoozoal diseases (giardia, amebiasis, trichomoniasis); however higher doses associated with CNS adverse effects Concentration dependent Within the bacteria: reduced and incorporates into bacterial DNA causing loss in helical structure inhibits nucleic acid synthesis results in cell death Bactericidal
264
Metronidazole Bioavailability, distribution, elimination
Good oral bioavailability Excellent tissue distribution with good penetration to BBB and CSF Elimination is dose dependent with renal and biliary routes Hepatic metabolism --> dose reduction with liver dysfunction Use with caution in patients with neurologic disease
265
Metronidazole Adverse effects
GI upset neurologic signs associated with higher doses and prolonged use Clinical signs: vertical nystagmus, ataxia, paraparesis, tetraparesis, hypermetria, head tilt, tremors Treatment: discontinue therapy and provide supportive care (IV fluids, antiemetics, sedatives PRN). Most patients improve within 3 days.
266
Chloramphenicol drug class mechanism of actions
Phenicol Bacteriostatic Inhibit protein synthesis by binding to 50S ribosomal subunit In mammalian cells, can also inhibit mitochondrial protein synthesis (especially erythropoietic cells).
267
Chloramphenicol effectiveness
Gram-positive Gram-negative anaerobic intracellular organisms such as: Chlamydia, mycoplasma and rickettsia Not effective against pseudomonas aeruginosa
268
Chloramphenicol bioavailability, metabolism and elimination
Good bioavailability through oral administration and tissue distribution Penetrates CNS Limited prostate Hepatic metabolism --> dose reduction with liver dysfunction Excreted in kidneys in mostly inactive form
269
Chloramphenicol Toxicity
Dose-dependent bone marrow suppression in humans, dogs and cats (cats more sensitive) **DO NOT SPLIT** **DO NOT PULVERIZE** Caretakers to wear gloves Dogs: hind end weakness and GI signs
270
Chloramphenicol + drugs requiring CYP450 (phenobarbital)
Chloramphenicol is a potent inhibitor of CYP450. Drugs that require CYP450 may need dose adjust to prevent toxicity.
271
Chloramphenicols + concurrent antimicrobials of other classes
Competitive inhibitors of 50S ribosomal subunits Do not give chloramphenicols with lincosamides and macrolides Tetracyclines bind to 30S subunit Therefore Chloramphenicols may act synergistically with tetracyclines
272
Clindamycin drug class Mechanism of action
Lincosamide Antimicrobial binds to 50S subunit of ribosome Bacteriostatic and time dependent
273
Clindamycin effectivness
Effective against gram-positive aerobes and anaerobes Effective against mycoplasma and toxoplasmosis
274
Clindamycin bioavailability Distribution, metabolism and elimination
Good bioavailability after oral administration. Can also be administered SQ and IV Good tissue distribution especially to skin and bone penetrates CNS penetrates blood prostate barrier --> good for gram-positive bacterial prostatitis penetrates biofilms --> use for gingivitis, and peridontal disease
275
Clindamycin Side effects
Overall rare Humans: overgrowth of C. diff
276
Doxycycline drug class Mechanism of actions
Tetracycline inhibits protein synthesis by binding to 30S ribosomal subunit bacteriostatic Lipid soluble --> greater bacterial penetration
277
Doxycycline effectiveness
1st line therapy for tick borne rickettsial diseases felin upper airway canine respiratory Gram-positive, gram-negative, mycoplasma, chlamydia, rickettsial, spirochetes not considered effective against anaerobic infections
278
Doxycycline resistance
found in all bacteria secondary to presence of efflux pumps alterations to binding sites bacterial enzymatic destruction
279
Doxycycline bioavailability distribution, metabolism and elimination
high bioavailability drug is lipophilic so will also distribute into placenta and milk limited in prostate highly protein bound 30%-40% CSF elimination: mostly unknown with 16% in urine unchanged predominance for intestinal elimination and enterohepatic recirculation
280
Doxycycline Adverse effects
Adverse effects more likely with decrease in rental function. Give with food to decrease GI upset Associated with ESOPHAGEAL EROSION - follow with 6ml water Incorporates into bone and enamel resulting in discoloration IV Doxycycline needs to be diluted and ideally given through central line to reduce risk of thrombophlebitis Give over 1 hour as anaphylactic shock has been reported Rarely hepatotoxic
281
Doxycycline Concurrent administration of medications and fluids
should not be administered with antacids, aspirin or calcium containing fluids as it chelates with cations May bind to cholestyramine because of its lipophilic nature
282
Sulfonamides and trimethoprim
individually - bacteriostatic used together = bactericidal and time dependent work on different stages of bacterial folic acid production Combo therapy 1:5 trimethoprim: sulfonamide
283
Sulfonamides and trimethoprim effectivess
broad spectrum gram-positive, gram-negative and anaerobes Ineffective against mycoplasma and rickettsial disease
284
Sulfonamides and trimethoprim distribution, metabolism and elimination
goo tissue distribution to include CNS for sulfadiazine and prostate for trimethoprim Both drugs undergo hepatic metabolism metabolites thought to be responsible for allergic and idiosyncratic reactions Both active drug and metabolites renally excreted TMS highly concentrated in urine therefore considered 1st line therapy for bacterial cystitis
285
Sulfonamides and trimethoprim Adverse effects
allogenic, immunogenic and toxic metabolites (Dobermans, Samoyeds and Mini schnauzers more sensitive) hypersensitivity reactions: fever, polyarthritis, pancreatitis, hepatitis, glomerulonephritis, anemia, ITP, mucosal skin lesions. KCS most common because of direct cytotoxic effects of sulfonamides on lacrimal gland reversible with short treatments (<5 days), but may be irreversible with long term use. decrease in thyroid hormone in dogs --> reversible
286
Macrolides Drug examples mechanism of actions
drugs: Erythromycin, azithromycin, clarithromycin Mechanism of action: binds to 50S subunit inhibiting protein synthesis Bacteriostatis
287
Macrolides effectiveness
Mainly effective against gram-positive bacteria and intracellular bacterial infections limited effectiveness against Gram-negative bacteria Not effective against anaerobic bacteria
288
Macrolides advantage
Alternative drug option for patients that cannot take beta-lactams (allergies)
289
Erythromycin
Macrolide enteral and parenteral administration rapid degradation by gastric acid when given orally DO NOT CRUSH TABLETS b/c coating helps prevent rapid degradation Drug of choice for Campylobacter jejuni
290
Azithromycin
Macrolide Greater activity against gram-negative organisms More stable in acid --> higher bioavailability when taken orally
291
Macrolides side effects
GI upset most commonly reported also highly effective as a prokinetic when administered at subantimicrobial doses
292
Nitrofurantoin
Prescription based on culture and susceptibility and lack of any other viable alternative treatment for multi drug resistant UTI inhibits cell wall synthesis, bacterial protein and DNA synthesis bactericidal Gram Positive and gram negative resistance is rare side effects: irreversible peripheral neuropathies use with caution in cats --> potential for hemolysis
293
Vancomycin
Prescription based on culture and susceptibility and lack of any other viable alternative glycopeptide antibiotic Reserved only for serious life-threatening multi-drug resistant gram-positive bacterial infections that cannot be treated with other agents (ie MRSA) Mechanism of action: inhibits proper cell wall synthesis by binding to subunits preventing cross-link formation in peptidoglycan cell wall Adverse effects: nephrotoxicity, ototoxicity Rapid IV administration can be associated with histamine release Extravasation can result in severe soft tissue damage
294
Rifampin
Prescription based on culture and susceptibility and lack of any other viable alternative used to treat Methicillin-resistant staphylococcal pyodermas Mechanism of action: inhibits RNA synthesis Resistance develops in as short as 2 days when used as monotherapy Use in combo with other drugs to decrease emergence to resistance Rifampin + fluoroquinolone --> antagonistic Fair to good oral bioavailability when fasted Side effects: GI upset and hepatotoxicity Pretreatment and weekly biochem monitoring for hepatotoxicity
295
Oxazolidinones
Prescription based on culture and susceptibility and lack of any other viable alternative Linezolid - synthetic antibiotic Treatment for multidrug resistant skin infections, pneumonia and bacteremia Mechanism of action: binds to p-site of 50S ribsomal subunit --> inhibit protein synthesis Bacteriostatic effective against gram-positive, including methicillin and vancomycin resistant staphylococci Anaerobic spectrum similar to clindamycin Good bioavailability with tissue distribution to lungs, CSF , bones well tolerated with dogs. No studies on cat pharmacokinetics
296
Lipopeptides
Prescription based on culture and susceptibility and lack of any other viable alternative Most recently discovered Drug: Daptomycin indicated for Gram-positive that are vancomycin resistant effective against gram-positive and anaerobic Mechanism of action: forms ion channels in cell membrane allowing it to depolarize and result in rapid cell death Gram-negative organisms inherently resistant Adverse effects: highly toxic, causes skeletal muscle damage
297
Antifungals (2 classes)
Polyene antibiotics Azole derivatives
298
polyene antibiotics two types
1. amphotericin B 2. lipid-complexed emphotericin B